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balance and decreased immunodefi ciency of the patient 
after major surgery7–9.
The use of mechanical bowel cleansing before colorec-
tal surgery is commonly practiced from almost the begin-
ning of this type of surgery10–11. This has been a standard 
procedure for surgeons for more than 100 years. The ra-
tionale is based on hypothesis that feces and bacteria in 
the operation fi eld could facilitate infection12. The idea is 
that the removal of GIT content preoperatively by me-
chanical cleansing will reduce the bacterial content and 
thus reduce the risk of wound infection, abdominal ab-
scesses, and even anastomotic dehiscence. However, re-
cently, several signifi cant trials and three meta-analyses 
suggest that there is no signifi cant benefi t of preoperative 
cleansing13–16.
Taking into account that preoperative cleansing can 
obviously be harmful and that hazard is likely related to 
the change in the quantity and composition of bacteria in 
the colon, it would be necessary to fi nd a procedure which 
would preserve the composition of bacteria and their pos-
itive effects.
Introduction
Despite advances in medicine and especially oncology 
and surgery in last decades there is no signifi cant rise of 
survival rate following colorectal surgery for cancer and 
also the complication rate remains almost the same1.
One of the important postoperative complications is 
without doubt postoperative infection or even sepsis. De-
spite the broad use of antibiotic prophylaxis these infec-
tions are still a very important reason for postoperative 
morbidity leading to prolonged hospital stay, increased 
costs or even higher mortality2.
The exact pathophysiological mechanism that predis-
poses patients undergoing major abdominal surgery to 
infection is not known. However, of major importance for 
the pathogenesis of postoperative infections is undoubt-
edly bacterial translocation from the gastrointestinal 
tract to the systemic circulation3–6. The main causes of 
bacterial translocation are generally an injury of the co-
lonic mucosa leading to disruption of the gut barrier and 
increased intestinal permeability as well as microbial im-
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fi bre includes polysaccharides, oligosaccharides, lignin, 
and associated plant substances and are called prebiotics. 
Those are non-digestible food ingredients that stimulate 
the growth and/or activity of bacteria in the digestive sys-
tem in ways claimed to be benefi cial to health.
The combination of specifi c bioactive microorganisms 
– probiotics and specifi c plant fi bers – prebiotics which can 
stimulate growth of certain microbes and which together 
have a synergistic effect is called synbiotic.
There are several possible mechanisms by which syn-
biotics have a benefi cial effect on the organism:
–  antagonistic activity against pathogenic bacteria ei-
ther by inhibition of adherence and translocation or 
by production of antibacterial substances,
–  modulation of barrier function,
–  modulation of intestinal cytokine production,
–  anti-infl ammatory properties, and
–  improvement of gut permeability27.
On the whole our idea was to administer »good bacte-
ria« (probiotics) and fi bers that stimulate their growth 
(prebiotics) to the patients with preceding colorectal sur-
gery and totally evade preoperative bowel cleansing. Our 
fi rst aim was to demonstrate the difference in the number 
of LAB in the colon mucosa between patients who received 
them and patients who did not. However, as we already 
mentioned above, the problem is that most of the LAB do 
not even reach the large bowel. Secondly, the degree of 
systemic infl ammatory response after surgery and pos-
sible positive clinical effect resulting in a smaller number 
of postoperative complications was also of crucial impor-
tance when conducting this study.
The results of our study may alter the algorithm and 
guidelines of the preoperative preparation not only in pa-
tients with colorectal cancer but also in patients undergo-
ing any other major abdominal surgery and thus diminish 
the patient’s morbidity and mortality as well as the hospi-
tal stay.
Materials and Methods
This was a prospective randomized, controlled, double 
blind trial of three groups. The study was performed at 
University Hospital Maribor, Slovenia and microbiology 
tests with polymerase chain reaction (PCR) were made at 
the Institute of Public Health Maribor, Slovenia.
A total number of 73 patients with preceding large 
bowel operation for colorectal cancer were recruited of 
whom 19 were excluded for various reasons.
Exclusion criteria were: Any chronic disease or health 
condition which in opinion of investigators may interfere 
with the patient’s ability to comply with protocol, place the 
subject at unnecessary risk, or interfere with the evalua-
tion of the study drugs, patients with signs or symptoms 
of bowel obstruction, patients who could not take the me-
chanic preoperative bowel preparation, and patients with 
chronic infl ammatory bowel disease. Some patients were 
removed from the study if one or more of the following had 
Prophylactic treatment with benefi cial bacteria might 
be one of the ways to achieve this. The presence of such 
bacteria in the gut results in prevention of overgrowth and 
predominance of potentially pathogenic microbes, which 
is also called colonization resistance17.
There is possibility that by adding so called »good bac-
teria« to severely ill and surgical patients we could prevent 
the overgrowth of pathogenic bacteria and all consequences 
of such an event. Such »good bacteria« is called probiotic. 
The Greek term probiotic means »for life« and is defi ned as 
a preparation of living microorganisms that change the 
micro fl ora and has positive effects on human health.
Probiotics are as a matter of fact live microorganisms 
thought to be benefi cial to the host organism and there 
have been many similar defi nitions in history18–20. Accord-
ing to the defi nition by FAO/WHO, probiotics are live mi-
croorganisms which, when administered in adequate 
amounts have a health benefi t on the host21. The most 
common types of microbes used as probiotics are lactic 
acid bacteria (LAB) and bifi d bacteria. In fact, probiotics 
are bacteria from normal gut fl ora, which are adminis-
tered orally.
It is very important that the probiotics utilized remain 
viable during GIT passage and that at least 107 cfu/ml of 
viable bacteria reach the intestine22. Only in this way we 
can aspect the clinical effect of ingested probiotics. Most 
probiotics currently advertised and sold do not meet this 
condition. As a matter of fact, the ability to survive the 
acidity of the stomach and bile acid content of the small 
intestine seems to be limited to very few microorganisms.
Another important fact to remember in choosing the 
right probiotic for clinical use is that only a small minor-
ity of LAB can ferment semi-resistant fi bers such as oli-
gofructans: inulin and phleins. When the ability of 712 
different LAB to ferment oligofructans was studied only 
16 of 712 were able to ferment the phleins and as little as 
8 of 712 the inulin type fi bre. Only four LAB species fer-
mented these fi bers: Lactobacillus plantarum (several 
strains), Lactobacillus paracasei subspecies paracasei, 
Lactobacillus brevis and Pediococcus pentosaceus23,24.
LAB also have the ability to control various pathogens, 
found in gut. This property is strain-specifi c and often 
limited to a few strains. When the ability of fi fty different 
LAB to control 23 different pathogenic Clostridium diffi -
cile strains was tested, only 5 proved effective against all, 
8 were antagonistic to some, but 27 were totally ineffec-
tive25. The fi ve most effective strains were Lactobacillus 
paracasei subspecies paracasei (2 strains) and Lactobacil-
lus plantarum (3 strains). Clearly information like this is 
important for choice of probiotics for clinical use.
For bacterial fermentation in lower GIT the presence 
of some plant dietary fi bres are of great necessity. Such 
fi bres also had a strong self-bioactivity. A recent defi nition 
by the American Association of Cereal Chemists suggests 
that dietary fi bre is: „the edible parts of plants or analo-
gous carbohydrates that are resistant to digestion and 
absorption in the human small intestine with complete or 
partial fermentation in the large intestine26. Such dietary 
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occurred: signifi cant protocol violation or non-compliance 
on the part of the patient, refusal of the patient to con-
tinue treatment or decision of the investigator that termi-
nation is in the patient’s best medical interest. In the end 
54 patients were eligible for statistical analysis.
Procedures and treatment
Patients were randomized in three groups with sealed 
opaque envelopes. Once a patient was consented to enter 
a trial an envelope was chosen and opened. According to 
this, the patient entered either group A, B or C.
Both synbiotics and prebiotics were stored in identical 
sachets with different labels, AA and AB. They were both, 
white powders, identical in weight, smell and taste. Thus 
the identity of the product was not known to participants 
or researchers until the end of the study.
Patients in all three groups started with a liquid diet 
two days prior to the operation. Patients in group A got 
one sachet marked AA twice a day three days before the 
operation. Patients in group B got one sachet marked AB 
twice a day three days before operation. Finally patients 
in group C received standard mechanic preoperative bow-
el preparation. On the day before surgery those patients 
were allowed a light breakfast. Afterwards they drank 75 
ml of ColoclensR. After few hours, afternoon patients had 
to consume 4 liters of hyperosmolar liquid Golitely, pro-
vided by the hospital pharmacy.
We estimated systemic infl ammatory response by re-
petitive measuring of C reactive protein (CRP) levels, pro-
infl ammatory cytokine interleukin-6 (IL-6) levels, fi brin-
ogen levels, white blood count and differential blood count. 
Samples of 10 ml blood were taken on the operation day, 
two hours prior to surgery, on day one and day three fol-
lowing the operation.
ASA scores (American Society of Anesthesiologists) 
were calculated at the time of surgery for each patient.
All patients received preoperatively one dose of antibi-
otic cefuroksim and metronidasole.
Several clinical data, fi rst oral solid food intake, fi rst 
peristalsis, passing of gasses and stool and complications 
were observed and recorded.
Patients were operated on in accordance with standard 
oncological principles.
There were only elective operations and no emergencies.
Two mucosal samples were taken immediately after 
the surgical specimen removal. They were store on ice and 
immediately transported to the laboratory for PCR ex-
amination. Oligonucleotide sequences specifi c for bacteria 
Lactobacillus paracasei, Lactobacillus mesenteroides, 
Lactobacillus plantarum, and Pediococcus pentosaceus 
were determined with real time PCR.
Isolation and purifi cation of DNA was performed with 
Qiagen DNA MiniKit under the strict manufacturer’s pro-
tocol.
Primers and probes were designed for detection of spe-
cifi c oligonucleotide sequences in target genes listed in 
Table 1. Detection of specifi c products was carried out 
by using fl uorescently labeled hydrolising probes (Taqman 
probes). Amplifi cation and detection was performed in 
ABI Prism 7000 Sequence Detection System.
In all samples, in which we confi rmed the oligonucle-
otide sequence characterized by at least one of the four bac-
teria, we performed relative quantifi cation of bacteri-
al species with real-time PCR. As reference gene we used 
the gen for beta-globin, which is part of the human ge-
nome.
All the procedures were in accordance with the Hel-
sinki Declaration. The study protocol received a full local 
research and ethics committee approval. Written informed 
consent was obtained from all patients.
Patient data were collected in special designed proto-
cols until discharge from hospital and data were analyzed 
on an intention to treat basis.
Medications used
The sachets marked AA contained Synbiotic 2000 
FORTE. It consists 1011 of each of four LAB: Pediacoccus 
pentosaceus 5–33:3, Leuconostoc mesenteroides 32–77:1, 
Lactobacillus paracasei subsp paracasei 19, and Lactoba-
cillus plantarum 2362. This makes 400 billion LAB per 
dose or if supplemented twice daily 800 billion LAB per 
day. Also included in the sachet is 2.5 g of each of the four 
fermentable fi bres – probiotics: betaglucan, inulin, pectin 
and resistant starch. Synbiotic 2000 FORTE was pro-
duced and marketed by Medipharm, Kageröd Sweden and 
Des Moines, Iowa, USA.
The sachets AB contained only prebiotics in the same 
amounts: 2.5 g of each of the four fermentable fi bres (pre-
biotics): betaglucan, inulin, pectin and resistant starch.
Coloclens (Senna glykosides) is an antraquinon laxa-
tive specially prepared for thorough preparation prior to 
abdominal surgery.
Golitely (Polyethylene glycol) is an osmotic agent, 
which is effective in cleansing the colon prior to elective 
colonic surgery.
Statistics
Qualitative data were presented with absolute frequen-
cies and numerical data with median and range values 
TABLE 1
TARGET GENES FOR THE PRIMERS AND PROBES
Bacteria Target gene
Lactobacillus paracasei putative pheromone PcrA
Leuconostoc mesenteroides acetat kinase
Lactobacillus plantarum luxS
Pediococcus pentosaceus collagen adhesion gene 1158
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due to distribution not following normal. Data analysis 
was performed using repeated measurements analysis of 
variance, and presented with distribution values F and 
P-values for within subject factor, between subject factor 
and the model as a whole. Only P-values lower than 0.05 
were considered signifi cant. Statistics was done using 
MedCalc (MedCalc software, ver. 11, Mariakerke, Bel-
gium).
Results
54 patients were eligible for the study. 20 in group A, 
18 in group B and 16 in group C. There were 21 women 
and 33 men. Median age was 65, for years between 43 and 
87. According to the ASA score we divided the patients 
into three groups: ASA 1, ASA 2 and ASA 3 and 4 to-
gether. Patients in all three groups were well matched for 
age, sex distribution, and ASA score and there were no 
signifi cant statistical differences between them (Table 2).
We performed 26 sigma resections, 16 right hemicolec-
tomies, 8 anterior rectal resection, 3 left hemicolectomies 
and one resection of transversal colon.
With PCR we determined a relative concentration of 
all four ingested LAB on colonic mucosa of all patients. 
The Kruskal-Wallis test was used to prove higher concen-
trations of lactobacilli in patients who received synbiotics 
preoperatively. The difference was statistically signifi cant 
for all four LAB (p < 0,0001). There was always a differ-
ence between group A and B or C, however there was no 
difference between groups B and C (Table 3).
On the other hand we found that there was no statisti-
cal signifi cant difference in systemic infl ammatory re-
sponse which was valued with three consecutive measure-
ments of CRP, IL-6(Table 4), fi brinogen, leukocyte count 
and differential blood count prior to operation, on the fi rst 
and third postoperative day.
There was the slight difference within groups but this 
was not statistically signifi cant.
TABLE 2
DEMOGRAPHIC ANALYSIS
Group A B C
No. 18 20 16
Sex; male/female 11/7 13/7 9/7
Age; median (range) 62 (43–87) y 64 (46–81) y 67 (52–78) y
ASA score; (median) 1.72 (1–3) 2.15 (2–3) 2.06 (1–3)
TABLE 3
RELATIVE NUMBER (MEDIAN) OF ISOLATED BACTERIA ON BOWEL MUCOSA CONSIDERING GROUPS A, B AND C
PAR MES PENT PLANT
median (min–max) median (min–max) median (min–max) median (min–max)
A 0.47 (0.1–33.2) 3.71 (0–2534) x 10E-3 3.36 (0.1–57.5) 0.27 (0–14.6)
B 2.18 (0–000) x 10E-2 0 (0–0.01) 0 (0–2.7) 0 (0–3.3)
C 8.73 (0–224) x 10E-3 0 (0–0.03) 0 (0–4.1) 0 (0–0.4)
Chi-Square 24.976 25.126 37.110 29.455
P < 0.01 < 0.01 < 0.01 < 0.01
PAR – Lactobacillus paracasei, MES – Lactobacillus mesenteroides, PENT – Pediococcus pentosaceus, PLANT – Lactobacillus plantarum
TABLE 4
THE VALUES OF THREE MEASUREMENTS OF IL-6 IN THE GROUPS AND THEIR COMPARISON ANALYSIS OF VARIANCE FOR 
REPEATED MEASUREMENTS (F, F-VALUE ANALYSIS OF VARIANCE, P, LEVEL OF SIGNIFICANCE).
IL-6 Groups F
prepeated measur. A B C Together
fi rst 2.6 (2–16) 5 (2–25) 4.05 (2–49) 3.95 (2–49) 96.70*
<0.001second 103.5 (6–235) 67.9 (9.9–323) 63.7 (21.5–224) 67.6 (6–323)







*  Comparison of repeated measurements (post-hoc test with p<0.05 differs fi rst from the second and fi rst from the third measurement, 
while the second and third measurements did not differ).
**  Comparison of values  between groups A, B and C.
***  Comparison of combined effect, ie the impact of belonging to groups A, B and C on repeated measurements.
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We also could not confi rm any statistically signifi cant 
differences for observed clinical data: fi rst peristalsis 
(FP), fi rst solid oral food intake (FSOFI), passing of gasses 
(POG) and passing of stool (POS).We detected a slight 
advantage in pre and synbiotic group, but there were no 
signifi cant differences (Table 5).
Medial hospitalization time after operation was 10.68 
days with minimum 7 and maximum 25 days. In group A 
median hospitalization time was 10.16, in group B 11.30 
and in group C 10.5 days. The hospitalization was longer 
in the control group but the difference was not statisti-
cally signifi cant (p=0.512).
There were no major complications. 9 patients had 
postoperative bowel paresis, four patients had wound in-
fection and two pneumonia. All complications were treat-
ed conservatively. The complication rate was low and we 
found no statistical differences between groups.
Discussion
The results of this study confi rmed that our choice of 
synbiotic was correct. We succeeded to detect the ingested 
LAB in much higher concentrations than in other groups. 
We decided to choose a mixture of four probiotics which 
had already been tested in several other studies and dem-
onstrated safe, and four different prebiotics28–32. The com-
position was constructed after large studies of > 350 hu-
man and >180 plant strains by microbiologists Asa Ljungh 
and Torkel Wadström from Lund university, Sweden (33, 
34). They have chosen the four LAB to be used in the 
composition based on the ability of the various LAB to 
produce bioactive proteins, transcribe nuclear factor kap-
pa-light-chain-enhancer of activated B cells (NF-.B), pro-
duce pro- and anti-infl ammatory cytokines ant antioxi-
dants, and to functionally complement each other. The 
four LAB individually operate differently, but show syn-
ergistic effects when supplemented together.
It is well known that LAB in commercial probiotics 
which are currently generally available in many cases do 
not pass the stomach, duodenum, and small bowel. They 
are destroyed and fermented by the strong gastric and 
duodenal juices and they do not even reach the large bow-
el. And the large bowel is the only part of digestive tract, 
where probiotics could be extremely useful.
This was the reason for us to try to prove and did prove 
that LAB in Synbiotic 2000 Forte were able to reach the 
fi nal part of digestive tract, the large bowel. PCR tests 
showed that all four LAB were present on the colonic mu-
cosa in signifi cantly higher ratio than in patients, who 
received only prebiotics and in patients who were preop-
erative cleansed.
We also hoped that synbiotics would have had a benefi -
cial effect on our patients in spite of lower postoperative 
infl ammation response, lower complication rate and of 
course shorter hospitalization which are very important 
goals for surgeons. Unfortunately we were not able to 
prove those benefi ts although we still believe in them.
In recent years several randomized controlled studies 
regarding pro and prebiotics in surgical patients have 
been published. Santvoort and al reviewed 14 randomized 
control studies on probiotics in surgical patients35. Nine 
showed a signifi cant decrease of total infectious complica-
tions in the patients treated with probiotics, but 5 studies 
could not demonstrate such an effect.
Rayes and al performed a review of 15 randomized con-
trol studies published up to 2008 (36). 12 studies showed 
at least a slight benefi t of probiotics, while three studies 
performed by the same group show no signifi cant positive 
effect of such treatment. Rayes explains those results by 
the relative short period of probiotic administration, oral 
route of administration and inhomogeneous distribution 
of operations with a high percentage of simple operations 
with low overall rates of infection.
In 2010 Gianotti et all published a randomized double 
blind trial regarding the preoperative application of pro-
biotics in patients with colorectal cancer (37). The probiot-
ics given were Bifi dobacterium longum and Lactobacillus 
johnsonii. The conclusion was that only La1 adheres to 
colonic mucosa and affects intestinal microbiota by reduc-
ing the concentration of pathogens and modulates local 
immunity.
In conclusion, the results of this prospective random-
ized double blind study suggest that after oral intake of 
Synbiotic 2000 Forte, which contains four LAB; those are 
found on colonic mucosa. The study also suggests that the 
application of synbiotic and prebiotic has no effect on sys-
temic infl ammatory response, measured by repetitive 
measurement of IL-6, CRP, differential blood count and 
TABLE 5
COMPARISON OF FIRST PERISTALSIS, FIRST SOLID FOOD INTAKE, FIRST PASSING OF GASSES AND FIRST PASSING OF STOOL 
BETWEEN THREE GROUPS (P, LEVEL OF SIGNIFICANCE)
Group A B C p
median (min–max) median (min–max) median (min–max)
FP 1.9 (1–3) 1.5 (1–3) 2.2 (1–4) 0.580
FSOFI median(min–max) 5.2 (2–10) 4.95 (3–10) 5.4 (3–9) 0.621
POG median(min–max) 2.7 (2–4) 2.5 (1–4) 2.8 (2–5) 0.873
POS median(min–max) 4.2 (2–8) 3.8 (2–6) 3.8 (2–6) 0.752
*First peristalsis (FP), fi rst solid oral food intake (FSOFI), passing of gasses (POG) and passing of stool (POS).
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fi brinogen and there is no effect considering postoperative 
course. However we feel that we should not generalize 
these results and that further studies with perhaps larger 
samples are required.
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PREBIOTSKO I SINBIOTSKO LIJEČENJE PRIJE KOLOREKTALNOG OPERACIJE – SLUČAJNI, 
DVOSTRUKO SLIJEPI TEST
S A Ž E T A K
Cilj našeg istraživanja bio je pokazati veće koncentracije bakterija mliječne kiseline (LAB) na sluznici debelog cri-
jeva kod operiranih pacijenata oboljelih od raka debelog crijeva liječenih preoperativnim oralnim unosom sinbiotika ili 
prebiotika. Također smo pokušali dokazati da je sustavni upalni odgovor nakon operacije nije tako težak kod bolesnika 
koji su uzimali sinbiotika ili prebiotike, nadalje, ovi pacijenti imaju manje postoperativnih komplikacija i povoljan post-
operativni tijek. 73 bolesnika s prethodnim kolorektalnim operacijama su regrutirani. Podijeljeni su u tri skupine. 
Jedna skupina je preoperativno dobila prebiotike, druga sinbiotike, a kod treće je preoperativni postupak čist. Defi ni-
rali smo broj četiri različite probiotičkih bakterija na sluznici debelog crijeva s lančanom reakcijom polimeraze (PCR). 
Serumske razine interleukina-6, CRP, fi brinogen, brojem bijelih krvnih stanica i diferencijalne pretrage krvi su vršene 
prije i nakon operacije radi određivanja sustavnih upalnih odgovora. Mi smo uspjeli potvrditi da je u sinobiotičkoj sku-
pini bilo je znatno više LAB-a prisutno na sluznici. Oni su prošli gornji dio gastrointestinalnog sustava te su izolirani 
na sluznici debelog crijeva. S druge strane, nismo pronašli nikakve statističke razlike u sustavnim upalnim reakcijama 
mjerenih gornjim faktorima i nije bilo razlike u postoperativnom tijeku i broju komplikacija između sve tri skupine.
